Met Life Investment Management, LLC Erasca, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 112,725 shares of ERAS stock, worth $176,978. This represents 0.0% of its overall portfolio holdings.
Number of Shares
112,725
Previous 103,686
8.72%
Holding current value
$176,978
Previous $283,000
0.35%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ERAS
# of Institutions
153Shares Held
221MCall Options Held
10.1KPut Options Held
79.3K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$30.4 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.7MShares$26.2 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$25.5 Million6.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$19.9 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA12.5MShares$19.6 Million4.12% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $192M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...